Literature DB >> 14563325

Bam32 links the B cell receptor to ERK and JNK and mediates B cell proliferation but not survival.

Arnold Han1, Kaoru Saijo, Ingrid Mecklenbräuker, Alexander Tarakhovsky, Michel C Nussenzweig.   

Abstract

Bam32 is an adaptor protein recruited to the plasma membrane upon B cell receptor (BCR) crosslinking in a phosphoinositol 3-kinase (PI3K)-dependent manner; however, its physiologic function is unclear. To determine its physiologic function, we produced Bam32-deficient mice. Bam32(-/-) B cells develop normally but have impaired T-independent antibody responses in vivo and diminished responses to BCR crosslinking in vitro. Biochemical analysis revealed that Bam32 acts in a novel pathway leading from the BCR to MAPK/ERK Kinases (MEK1/2), MAPK/ERK Kinase Kinase-1 (MEKK1), extracellular signal-regulated kinase (ERK), and c-jun NH2-terminal kinase (JNK), but not p38 mitogen-activated protein kinase (p38). This pathway appears to be initiated by hematopoietic progenitor kinase-1 (HPK1), which interacts directly with Bam32, and differs from all previously characterized BCR signaling pathways in that it is required for normal BCR-mediated proliferation but not for B cell survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14563325     DOI: 10.1016/s1074-7613(03)00275-9

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  26 in total

1.  Molecular characterization of in vivo adjuvant activity in ferrets vaccinated against influenza virus.

Authors:  Yuan Fang; Thomas Rowe; Alberto J Leon; David Banner; Ali Danesh; Luoling Xu; Longsi Ran; Steven E Bosinger; Yi Guan; Honglin Chen; Cheryl C Cameron; Mark J Cameron; David J Kelvin
Journal:  J Virol       Date:  2010-06-09       Impact factor: 5.103

Review 2.  The cytoskeleton coordinates the early events of B-cell activation.

Authors:  Naomi E Harwood; Facundo D Batista
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-02-01       Impact factor: 10.005

3.  Genome-wide identification of TAL1's functional targets: insights into its mechanisms of action in primary erythroid cells.

Authors:  Mira T Kassouf; Jim R Hughes; Stephen Taylor; Simon J McGowan; Shamit Soneji; Angela L Green; Paresh Vyas; Catherine Porcher
Journal:  Genome Res       Date:  2010-06-21       Impact factor: 9.043

4.  3BP2 deficiency impairs the response of B cells, but not T cells, to antigen receptor ligation.

Authors:  Miguel A de la Fuente; Lalit Kumar; Bao Lu; Raif S Geha
Journal:  Mol Cell Biol       Date:  2006-07       Impact factor: 4.272

5.  Dendritic cell-dependent inhibition of B cell proliferation requires CD22.

Authors:  Lorna Santos; Kevin E Draves; Mark Boton; Prabhjit K Grewal; Jamey D Marth; Edward A Clark
Journal:  J Immunol       Date:  2008-04-01       Impact factor: 5.422

6.  Diacylglycerol kinase ζ limits B cell antigen receptor-dependent activation of ERK signaling to inhibit early antibody responses.

Authors:  Matthew L Wheeler; Matthew B Dong; Robert Brink; Xiao-Ping Zhong; Anthony L DeFranco
Journal:  Sci Signal       Date:  2013-10-15       Impact factor: 8.192

7.  Dual role of hematopoietic progenitor kinase 1 (HPK1) as a positive regulator of 1α,25-dihydroxyvitamin D-induced differentiation and cell cycle arrest of AML cells and as a mediator of vitamin D resistance.

Authors:  Xiangwen Chen-Deutsch; George P Studzinski
Journal:  Cell Cycle       Date:  2012-04-01       Impact factor: 4.534

Review 8.  Signaling mechanisms regulating B-lymphocyte activation and tolerance.

Authors:  Elias Hobeika; Peter J Nielsen; David Medgyesi
Journal:  J Mol Med (Berl)       Date:  2015-01-29       Impact factor: 4.599

Review 9.  Mechanisms of central tolerance for B cells.

Authors:  David Nemazee
Journal:  Nat Rev Immunol       Date:  2017-04-03       Impact factor: 53.106

10.  Activation of hematopoietic progenitor kinase 1 involves relocation, autophosphorylation, and transphosphorylation by protein kinase D1.

Authors:  Rüdiger Arnold; Irene M Patzak; Brit Neuhaus; Sadia Vancauwenbergh; André Veillette; Johan Van Lint; Friedemann Kiefer
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.